Donation after cardiac death (DCD) and acute kidney injury (AKI) donors have historically been considered independent risk factors for delayed graft function (DGF), allograft failure, and inferior outcomes. With growing experience, updated analyses have shown good outcomes. There however continues to be limited data on outcomes specific to DCD donors who have AKI. Primary outcomes for this study were post‐kidney transplant patient and allograft survival comparing two donor groups: DCD AKIN stage 2‐3 and DBD AKIN stage 2‐3. In comparing these groups, there were no short‐ or long‐term differences in patient (HR 1.07, 95% CI 0.54‐1.93, p=0.83) or allograft survival (HR 1.47, 95% CI 0.64‐2.97, p=0.32). In multivariate models, the DCD/DBD status had no significant impact on the eGFR at 1‐ (p=0.38), 2‐ (p=0.60), and 3‐years (p=0.52). DGF (57.9% vs. 67.9%, p=0.09), rejection (12.1% vs. 13.9%, p=0.12), and progression of interstitial fibrosis/tubular atrophy (IFTA) on protocol biopsy (p=0.16) were similar between the two groups. With careful selection, good outcomes can be achieved utilizing severe AKI DCD kidneys. Historic concerns regarding primary non‐function, DGF resulting in interstitial fibrosis and rejection, and inferior outcomes were not observed. Given the ongoing organ shortage, increased effort should be undertaken to further utilize these donors.